JP2013516501A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516501A5
JP2013516501A5 JP2012549006A JP2012549006A JP2013516501A5 JP 2013516501 A5 JP2013516501 A5 JP 2013516501A5 JP 2012549006 A JP2012549006 A JP 2012549006A JP 2012549006 A JP2012549006 A JP 2012549006A JP 2013516501 A5 JP2013516501 A5 JP 2013516501A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
halogen
nhcor
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012549006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020871 external-priority patent/WO2011085385A1/en
Publication of JP2013516501A publication Critical patent/JP2013516501A/ja
Publication of JP2013516501A5 publication Critical patent/JP2013516501A5/ja
Pending legal-status Critical Current

Links

JP2012549006A 2010-01-11 2011-01-11 マイボーム腺機能障害を治療する方法 Pending JP2013516501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29396610P 2010-01-11 2010-01-11
US61/293,966 2010-01-11
PCT/US2011/020871 WO2011085385A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Publications (2)

Publication Number Publication Date
JP2013516501A JP2013516501A (ja) 2013-05-13
JP2013516501A5 true JP2013516501A5 (https=) 2014-04-10

Family

ID=44259000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549006A Pending JP2013516501A (ja) 2010-01-11 2011-01-11 マイボーム腺機能障害を治療する方法

Country Status (10)

Country Link
US (1) US8791158B2 (https=)
EP (1) EP2523556A4 (https=)
JP (1) JP2013516501A (https=)
KR (1) KR20120115380A (https=)
CN (1) CN103002737A (https=)
AU (1) AU2011203832A1 (https=)
CA (1) CA2787114A1 (https=)
MX (1) MX2012008110A (https=)
RU (1) RU2012134351A (https=)
WO (1) WO2011085385A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) * 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
ES2581765T3 (es) * 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RU2567829C1 (ru) * 2014-10-22 2015-11-10 Елизавета Геннадьевна Полунина Способ оценки морфофункционального состояния мейбомиевых желез - биометрия мейбомиевых желез
KR101714710B1 (ko) 2015-09-17 2017-03-10 고려대학교 산학협력단 마이봄샘 압출기
US11040062B2 (en) * 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN116183427A (zh) * 2021-11-29 2023-05-30 巴西石油公司 用于评估延迟焦化装置的炉的管中的沉积的系统和方法
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) * 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JPWO2002022585A1 (ja) * 2000-09-14 2004-01-22 科研製薬株式会社 テトラヒドロキノリン化合物
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
AU2003216153B2 (en) 2002-02-28 2008-01-24 The University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7705182B2 (en) * 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2005529952A (ja) 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション N架橋選択的アンドロゲン受容体修飾物質及びその使用方法
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
EP1562906A4 (en) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
WO2004034978A2 (en) 2002-10-15 2004-04-29 Gtx, Inc. Treating obesity with selective androgen receptor modulators
CA2502209A1 (en) 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040265916A1 (en) * 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
WO2004035739A2 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JP4603528B2 (ja) * 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
AU2004206909A1 (en) 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (ADIF)-associated conditions with sarms
WO2005060647A2 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20070082017A1 (en) * 2004-01-10 2007-04-12 Tseng Scheffer C Lipid compositions and methods of use
PL1753417T3 (pl) 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20130034562A1 (en) * 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
JP4899625B2 (ja) * 2006-05-12 2012-03-21 スズキ株式会社 鞍乗型不整地走行車両
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
BRPI0713198A2 (pt) * 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
ES2581765T3 (es) * 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
BRPI0808410A2 (pt) * 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
US7968603B2 (en) * 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN103553966B (zh) * 2007-09-11 2016-09-07 Gtx公司 选择性雄激素受体调节剂的固体形态
HUE024146T2 (en) * 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication

Similar Documents

Publication Publication Date Title
JP2013516501A5 (https=)
RU2012134351A (ru) Способы лечения дисфункции мейбомиевых желез
JP7457401B2 (ja) 毒性アルデヒド関連疾患および処置
CN105307498B (zh) 用于治疗眼病的组合物、制剂和方法
US12403114B2 (en) Cannabinoid acid ester compositions and uses thereof
JP2015521166A5 (https=)
US20260069618A1 (en) Cannabinoid acid ester compositions and uses thereof
JP2017513824A5 (https=)
MX2011005869A (es) Metodos para prevenir o reducir carcinogenesis de colon.
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
WO2019129249A1 (zh) 含三萜类化合物的药物组合物及其用途
JP2018024677A (ja) ラキニモドを使用する眼炎症性疾患の治療
ES2324130B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular.
JP7038437B2 (ja) 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法
JP2023089077A (ja) N-アセチル又はn-アシルアミノ酸を含むアトピー又は痒み症治療用組成物
US11717513B2 (en) Mirabegron for the treatment of retinal diseases
RU2019136633A (ru) Лечение глаукомы
CN103191110A (zh) 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用
US20080306163A1 (en) Agent for treatment of allergic eye disease
CN102225896A (zh) 大黄酸的醚衍生物以及它们的治疗用途
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
CN101678032A (zh) 使用氟喹诺酮调节炎症的组合物以及方法
CN108348516B (zh) 外用剂
ES2717481T3 (es) Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos
TW201740977A (zh) 用於緩解及治療搔癢病之方法